ViiV pulls app for new Selzentry indication; U.S. Hikma unit aims for CMO growth on drug shortages;

@FiercePharma: Scientists who worked on targeted leukemia meds--Novartis' Gleevec, BMS' Sprycel--make Nobel predictions list Story | Follow @FiercePharma

> ViiV Healthcare, the HIV concern jointly owned by GlaxoSmithKline ($GSK) and Pfizer ($PFE), has pulled its appication for a new once-daily indication for its drug Celsentri/Selzentry, saying it needs additional data. Report

> Hikma Pharmaceuticals said its U.S. unit West-Ward would focus on contract manufacturing growth, seeing an opportunity in the increasing number of drug shortages in the country. Release

> Johnson & Johnson's ($JNJ) Janssen unit launched its new prostate cancer pill Zytiga in the U.K. Item

> Jazz Pharmaceuticals ($JAZZ) stock set a new high after it announced a deal to merge with Ireland's Azur Pharma in an all-stock transaction. More

> Abbott Laboratories ($ABT) shares gained after a Jeffries analyst said the company is undervalued compared with the rest of pharma. Report

> Express Scripts ($ESRX) and Medco Health Solutions ($MHS) executives touted benefits of their proposed merger on Capitol Hill but investors remain skeptical that the deal will pass regulatory scrutiny, Reuters says. Story

> Takeda Pharmaceutical rolled out two dosages of its type 2 diabetes drug Liovel in Japan. Article

> Strides Arcolab got the FDA nod for its version of the high-powered antibiotic vancomycin. News

> Pharmacy services firm PharMerica ($PMC) said its board unanimously rejected Omnicare's ($OCR) $15-per-share hostile bid for the company. Release

Biotech News

@FierceBiotech: Report: Just 10% of drug moving through trials between 2003 and 2010 were approved by FDA. Oncology drugs faced toughest road. More | Follow @FierceBiotech

@JohnCFierce: Creating co. on bleeding edge of a new technology can cut both ways. PacBio axes 130 jobs, slams brakes on spending. News | Follow @JohnCFierce

@RyanMFierce: I hope to see lots of Boston biotechies at Oct. 19 breakfast featuring R&D heads at Biogen, Vertex and @JohnCFierce. Info | Follow @RyanMFierce

@MaureenFierce: RT @thecortex: Merck boss uses 12 different names for "job-cut" in memo. Report | Follow @MaureenFierce

> Pacific Biosciences axes 130 jobs as it slams brakes on spending. Piece

> Orexigen will mount $100M comeback try for spurned weight drug. News

> Hospira preps PhIII biosimilar study as it grabs lead on new market. Item

Medical Device News

@FierceMedDev: Medtronic awarded $101.2M in patent infringement case. Article | Follow @FierceMedDev

> Medtronic awarded $101.2M in patent infringement case. More

> Boston Sci prevails in lawsuit over sales group. Story

> Former Wright exec takes reins at Intrinsic. Report

Drug Delivery News

> Feds back nasal med for cyanide poisoning. Report

> Lasers craft neuron-delivery 'trucks' for Alzheimer's. Piece

> Ultrasound could aid delivery of drugs into brain. Item

> Alkermes wraps buyout of Elan drug-delivery biz. Story

> Unigene, Tarsa score Ph3 win with oral peptide drug. Item

> Sanofi fuels microneedle trend with flu vax. More

And Finally... The World Health Organization reports a new polio outbreak in China after vaccination campaigns faltered. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.